Next, to further verify the clinical significance of SOX6 and MAP4K4 protein levels in cervical cancer patients with routine cisplatin treatment, we collected the cervical cancer tissues from 14 cervical cancer patients after receiving routine cisplatin treatment, half of whom were sensitive to chemotherapy according to the new guidelines to evaluate the response to treatment in solid tumors [43]. This evidence concerns the gene MAP4K4 and cervical carcinoma.